“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO
Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say
You may also be interested in...
Daiichi Gets Into Generics With Stake In Ranbaxy
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at http://invivoblog.blogspot.com/.
Bristol Recharges Kai Heart Attack Candidate
Just because a marriage ends with a breakup doesn't mean a happy union with someone else isn't in the stars - especially when it comes to partnerships between big pharma and biotech
Merck Hopes To Make A Success Story of CETP Inhibitors And Obesity Drugs
Merck is hoping to find success where other firms have failed: its late stage pipeline includes two programs in drug classes where the lead candidates from other companies have not managed to gain approval